In December 2018, an article summarizing available results of randomized studies on renal denervation (RDN), entitled "Renal denervation: can we press the ON button again?" was published in the . Since then, several positive reports, including SPYRAL HTN OFF-MED Pivotal trial have been presented. In the current review the authors discuss the latest data on RDN in arterial hypertension treatment and try to answer the burning question: can we press the ON button again in 2020? The results of recently published studies potentially justify new recommendations for the use of RDN in clinical practice in appropriately selected patients in the new hypertension guidelines. The current review also summarizes the results of trials on RDN applied in another potential indication - atrial fibrillation. Six most important, prospective, randomized trials assessing RDN as adjunct therapy to pulmonary vein isolation for treatment of atrial fibrillation were discussed. In 5 studies, patients had uncontrolled BP despite treatment with three antihypertensive agents. The ratio for recurrence of atrial fibrillation for pulmonary vein isolation with RDN procedure was reduced by 57% as compared to pulmonary vein isolation (PVI) alone. BP was also reduced significantly after RDN in this subset of patients. Further multicenter studies involving standardized PVI and RDN procedures are needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863814PMC
http://dx.doi.org/10.5114/aic.2020.99260DOI Listing

Publication Analysis

Top Keywords

atrial fibrillation
12
pulmonary vein
12
vein isolation
12
renal denervation
8
denervation press
8
button 2020?
8
rdn
8
press button
8
current review
8
press "on"
4

Similar Publications

This post-market clinical follow-up (PMCF) study evaluates the clinical effectiveness and safety of the external radio electric reprogramming for atrial fibrillation (EX-RER AF) protocol, a non-invasive regenerative medicine approach utilizing radio electric asymmetric conveyer (REAC) technology for managing paroxysmal atrial fibrillation (PAF). Administered with the REAC BENE mod 110 device (ASMED, Scandicci, Italy), the treatment involves a standardized procedure, with the asymmetric conveyor probe (ACP) positioned in the precordial area and fixed, unmodifiable parameters ensuring consistency and reproducibility. During a 36-month post-market clinical follow-up (PMCF), 20 patients with prior diagnoses of PAF underwent the protocol.

View Article and Find Full Text PDF

Introduction: Atrial fibrillation (AFib) is a common disorder featured by an irregular and fast heartbeat. The etiology of AFib is complex and involves genetic and environmental factors. The rs2200733 single nucleotide polymorphism (SNP) is located in close proximity to the promoter of paired-like homeodomain transcription factor 2 (PITX2) which plays a role in heart development.

View Article and Find Full Text PDF

In the early stages of atrial fibrillation (AF), most cases are paroxysmal (pAF), making identification only possible with continuous and prolonged monitoring. With the advent of wearables, smartwatches equipped with photoplethysmographic (PPG) sensors are an ideal approach for continuous monitoring of pAF. There have been numerous studies demonstrating successful capture of pAF events, especially using deep learning.

View Article and Find Full Text PDF

Patient Characteristics and Real-World Treatment of Very Elderly Patients with Nonvalvular Atrial Fibrillation in Japan: An Administrative Claims Database Study.

Cardiol Ther

December 2024

Internal Medicine Medical Affairs, Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-Ku, Tokyo, 151-8589, Japan.

Introduction: Very elderly patients with nonvalvular atrial fibrillation (NVAF) are at high risk for both ischemic and hemorrhagic events. This study aimed to understand the characteristics and real-world treatment of very elderly patients with NVAF in Japan.

Methods: We conducted a retrospective analysis of electronic health records and claims data from acute care hospitals for very elderly patients with NVAF with medical records available on or after their 80th birthday.

View Article and Find Full Text PDF

Risk of mortality between warfarin and direct oral anticoagulants: population-based cohort studies.

BMC Med

December 2024

Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology & Population Health, London, School of Hygiene and Tropical Medicine, London, UK.

Background: Direct oral anticoagulants (DOACs) have been reported to be associated with a higher risk of mortality compared with an older alternative, warfarin using primary care data in the United Kingdom (UK). However, other studies observed contradictory findings. We therefore aimed to investigate the association between mortality and warfarin, compared with DOACs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!